Literature DB >> 6325431

Site-specific recognition of bacteriophage T4 DNA by T4 type II DNA topoisomerase and Escherichia coli DNA gyrase.

K N Kreuzer, B M Alberts.   

Abstract

The site specificity of bacteriophage T4-induced type II DNA topoisomerase action on double-stranded DNA has been explored by studying the sites where DNA cleavages are induced by the enzyme. Oxolinic acid addition increases the frequency at which phi X174 duplex DNA is cut by the enzyme by about 100-fold, to the point where nearly every topoisomerase molecule causes a double-stranded DNA cleavage event. The effect of oxolinic acid on the enzyme is very similar to its effect on another type II DNA topoisomerase, the Escherichia coli DNA gyrase. A filter-binding method was developed that allows efficient purification of topoisomerase-cleaved DNA fragments by selecting for the covalent attachment of this DNA to the enzyme. Using this method, T4 topoisomerase recognition of mutant cytosine-containing T4 DNA was found to be relatively nonspecific, whereas quite specific recognition sites were observed on native T4 DNA, which contains glucosylated hydroxymethylcytosine residues. The increased specificity of native T4 DNA recognition seems to be due entirely to the glucose modification. In contrast, E. coli DNA gyrase shows a high level of specificity for both the mutant cytosine-containing DNA and native T4 DNA, recognizing about five strong cleavage sites on both substrates. An unexpected feature of DNA recognition by the T4 topoisomerase is that the addition of the cofactor ATP strongly stimulates the topoisomerase-induced cleavage of native T4 DNA, but has only a slight effect on cleavage of cytosine-containing T4 DNA.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6325431

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.

Authors:  G Hong; K N Kreuzer
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  Escherichia coli replication factor Y, a component of the primosome, can act as a DNA helicase.

Authors:  M S Lee; K J Marians
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

3.  DNA and RNA-DNA annealing activity associated with the tau subunit of the Escherichia coli DNA polymerase III holoenzyme.

Authors:  S Kim; K J Marians
Journal:  Nucleic Acids Res       Date:  1995-04-25       Impact factor: 16.971

4.  Archaebacterial reverse gyrase cleavage-site specificity is similar to that of eubacterial DNA topoisomerases I.

Authors:  O I Kovalsky; S A Kozyavkin; A I Slesarev
Journal:  Nucleic Acids Res       Date:  1990-05-11       Impact factor: 16.971

5.  Bacteriophage T4 DNA topoisomerase mediates illegitimate recombination in vitro.

Authors:  H Ikeda
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

6.  Topoisomerase II and other DNA-delay and DNA-arrest mutations impair bacteriophage T4 DNA packaging in vivo and in vitro.

Authors:  A Zachary; L W Black
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

7.  Replication and supercoiling of simian virus 40 DNA in cell extracts from human cells.

Authors:  B W Stillman; Y Gluzman
Journal:  Mol Cell Biol       Date:  1985-08       Impact factor: 4.272

8.  Sequence specificity of Bacillus subtilis DNA gyrase in vivo.

Authors:  V I Bashkirov; D J Zvingila
Journal:  Genetica       Date:  1991       Impact factor: 1.082

9.  Frameshift mutations produced by proflavin in bacteriophage T4: specificity within a hotspot.

Authors:  L S Ripley; A Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

10.  The specificity of topoisomerase-mediated DNA cleavage defines acridine-induced frameshift specificity within a hotspot in bacteriophage T4.

Authors:  M Masurekar; K N Kreuzer; L S Ripley
Journal:  Genetics       Date:  1991-03       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.